QL1706 Clinical Trials
15 recruitingDrug
Phase 212Phase 32Phase 12Not Applicable1
Showing 1–15 of 15 trials
Recruiting
Phase 2
SKB264 Plus QL1706 in Recurrent or Metastatic Cervical Cancer
Cervical Cancer
Fujian Cancer Hospital89 enrolled14 locationsNCT07256236
Recruiting
Phase 2
SCRT(Short Course Radiotherapy) Combined With CAPOX Plus QL1706 for Rectal Cancer Liver Metastases
Locally Advanced Rectal Cancer With Liver Metastases
Fujian Cancer Hospital42 enrolled2 locationsNCT06787183
Recruiting
Phase 2
QL1706 Plus Chidamide, AG as First-line Treatment for Metastatic Pancreatic Cancer
Metastatic Pancreatic Cancer
Tianjin Medical University Cancer Institute and Hospital33 enrolled1 locationNCT06951997
Recruiting
Phase 2
QL1706 for the Neoadjuvant Treatment of HR+/HER2- Breast Cancer
Breast CancerHR+/HER2- Breast Cancer
Henan Cancer Hospital238 enrolled1 locationNCT06967103
Recruiting
Phase 3
A Study of Neoadjuvant QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
Colon Cancer
Qilu Pharmaceutical Co., Ltd.363 enrolled1 locationNCT06686576
Recruiting
Phase 1Phase 2
A Study of QLC5508 Combinations in Patients With Advanced Solid Tumors
Advanced Solid Tumor
Qilu Pharmaceutical Co., Ltd.444 enrolled1 locationNCT07256782
Recruiting
Phase 2
Iparomlimab and Tuvonralimab (QL1706) in Patients With HR-positive, HER2-negative Advanced Breast Cancer
Advanced Breast Cancer
Wenjin Yin123 enrolled1 locationNCT07180160
Recruiting
Phase 2
First-line Regimen With QL1706 Plus Chemo ± Bev in PDAC Patients
Pancreatic Cancer
Fudan University58 enrolled1 locationNCT06313970
Recruiting
Phase 2
Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC
Non-small Cell Lung Cancer (NSCLC)II-IIIB
Cancer Institute and Hospital, Chinese Academy of Medical Sciences90 enrolled1 locationNCT06897046
Recruiting
Phase 2
QL1706 Combined With Lenvatinib and GEMOX as First - Line Treatment for Unresectable Biliary Tract Tumors
Biliary Tract Tumors
Eastern Hepatobiliary Surgery Hospital59 enrolled1 locationNCT06892925
Recruiting
Not Applicable
Individualized Comprehensive Treatment for Advanced Hepatocellular Carcinoma
Nanjing Tianyinshan Hospital300 enrolled1 locationNCT06893887
Recruiting
Phase 3
QL1706 (PD-1/CTLA-4 Bi-specific Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma.
Nasopharyngeal CancerNasopharyngeal Cancinoma (NPC)
Sun Yat-Sen University Cancer Center580 enrolled19 locationsNCT06749899
Recruiting
Phase 1Phase 2
Iparomlimab and Tuvonralimab (QL1706) for Intermediate Trophoblastic Tumors
Intermediate Trophoblastic Tumor
Peking Union Medical College Hospital20 enrolled1 locationNCT06941766
Recruiting
Phase 2
QL1706 Plus Chemotherapy +/- Bevacizumab in 1L Treatment of R/mTNBC
Fudan University60 enrolled1 locationNCT06786026
Recruiting
Phase 2
A Phase II Study of CRT Combined With QL1706 in ESCC Patients
Esophageal Squamous Cell Carcinoma
Tianjin Medical University Cancer Institute and Hospital39 enrolled1 locationNCT05490719